Immunic, Inc. saw a boost in analyst confidence on Monday. HC Wainwright significantly raised its earnings per share forecasts for the company, now projecting a smaller loss of $3.18 per share in 2026 and anticipating profitability by 2030. The firm maintained its "Buy" rating and a $22 price target.
Adding to the positive sentiment, Wedbush initiated coverage of Immunic with an "Outperform" rating and a $45 price target. Wedbush highlighted the potential of Immunic's lead program, vidofludimus calcium for multiple sclerosis, noting its promising safety profile and the overall underappreciated opportunity in the MS market. The company's strong cash position, which is expected to fund operations into late 2027, was also noted as a key strength supporting its development programs.